Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 105.93
TRGT's Cash to Debt is ranked higher than
74% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. TRGT: 105.93 )
TRGT' s 10-Year Cash to Debt Range
Min: 11.33   Max: No Debt
Current: 105.93

Equity to Asset 0.93
TRGT's Equity to Asset is ranked higher than
94% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. TRGT: 0.93 )
TRGT' s 10-Year Equity to Asset Range
Min: -5.8   Max: 0.95
Current: 0.93

-5.8
0.95
F-Score: 2
Z-Score: 4.39
M-Score: 140.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1301.07
TRGT's Operating margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. TRGT: -1301.07 )
TRGT' s 10-Year Operating margin (%) Range
Min: -2537.37   Max: 15.3
Current: -1301.07

-2537.37
15.3
Net-margin (%) -1286.99
TRGT's Net-margin (%) is ranked higher than
55% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. TRGT: -1286.99 )
TRGT' s 10-Year Net-margin (%) Range
Min: -2456.95   Max: 12.72
Current: -1286.99

-2456.95
12.72
ROE (%) -34.70
TRGT's ROE (%) is ranked higher than
67% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. TRGT: -34.70 )
TRGT' s 10-Year ROE (%) Range
Min: -57.11   Max: 11.87
Current: -34.7

-57.11
11.87
ROA (%) -32.02
TRGT's ROA (%) is ranked higher than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. TRGT: -32.02 )
TRGT' s 10-Year ROA (%) Range
Min: -103.54   Max: 4.15
Current: -32.02

-103.54
4.15
ROC (Joel Greenblatt) (%) -6923.17
TRGT's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. TRGT: -6923.17 )
TRGT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6923.17   Max: 215.99
Current: -6923.17

-6923.17
215.99
Revenue Growth (%) -66.20
TRGT's Revenue Growth (%) is ranked higher than
55% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. TRGT: -66.20 )
TRGT' s 10-Year Revenue Growth (%) Range
Min: -67.4   Max: 68.8
Current: -66.2

-67.4
68.8
» TRGT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

TRGT Guru Trades in Q2 2013

Chuck Royce 40,000 sh (New)
Jim Simons 266,879 sh (-18.85%)
» More
Q3 2013

TRGT Guru Trades in Q3 2013

Jim Simons 314,397 sh (+17.81%)
Chuck Royce 40,000 sh (unchged)
» More
Q4 2013

TRGT Guru Trades in Q4 2013

Chuck Royce 40,000 sh (unchged)
Jim Simons 143,059 sh (-54.5%)
» More
Q1 2014

TRGT Guru Trades in Q1 2014

Chuck Royce Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TRGT

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 Sold Out 0.01%$3.99 - $4.78 $ 3.91-12%0
Jean-Marie Eveillard 2012-09-30 Reduce -58.86%0.01%$4.22 - $5.12 $ 3.91-14%600000
Seth Klarman 2012-03-31 Sold Out 1%$5.03 - $7.5 $ 3.91-34%0
Jean-Marie Eveillard 2012-03-31 Add 584.3%0.02%$5.03 - $7.5 $ 3.91-34%1368600
Seth Klarman 2011-12-31 New Buy1%$4.99 - $19.25 $ 3.91-66%6000000
Jean-Marie Eveillard 2011-12-31 New Buy$4.99 - $19.25 $ 3.91-66%200000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.10
TRGT's P/B is ranked higher than
97% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. TRGT: 1.10 )
TRGT' s 10-Year P/B Range
Min: 0.7   Max: 12.59
Current: 1.1

0.7
12.59
P/S 714.29
TRGT's P/S is ranked lower than
53% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. TRGT: 714.29 )
TRGT' s 10-Year P/S Range
Min: 0   Max: 708.9
Current: 714.29

0
708.9
EV-to-EBIT -0.71
TRGT's EV-to-EBIT is ranked higher than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TRGT: -0.71 )
TRGT' s 10-Year EV-to-EBIT Range
Min: 21.8   Max: 48.2
Current: -0.71

21.8
48.2
Current Ratio 9.98
TRGT's Current Ratio is ranked higher than
89% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. TRGT: 9.98 )
TRGT' s 10-Year Current Ratio Range
Min: 2.15   Max: 15.1
Current: 9.98

2.15
15.1
Quick Ratio 9.98
TRGT's Quick Ratio is ranked higher than
89% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. TRGT: 9.98 )
TRGT' s 10-Year Quick Ratio Range
Min: 2.15   Max: 15.1
Current: 9.98

2.15
15.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.50
TRGT's Price/Net Cash is ranked higher than
99% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. TRGT: 1.50 )
TRGT' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 17.79
Current: 1.5

1.03
17.79
Price/Net Current Asset Value 1.50
TRGT's Price/Net Current Asset Value is ranked higher than
99% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. TRGT: 1.50 )
TRGT' s 10-Year Price/Net Current Asset Value Range
Min: 1.02   Max: 48.6
Current: 1.5

1.02
48.6
Price/Tangible Book 1.10
TRGT's Price/Tangible Book is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. TRGT: 1.10 )
TRGT' s 10-Year Price/Tangible Book Range
Min: 0.73   Max: 11.55
Current: 1.1

0.73
11.55
Price/Median PS Value 0.70
TRGT's Price/Median PS Value is ranked higher than
56% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. TRGT: 0.70 )
TRGT' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 4.91
Current: 0.7

0.32
4.91
Earnings Yield (Greenblatt) 4.50
TRGT's Earnings Yield (Greenblatt) is ranked higher than
67% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. TRGT: 4.50 )
TRGT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 4.6
Current: 4.5

2.1
4.6
Forward Rate of Return (Yacktman) -8.48
TRGT's Forward Rate of Return (Yacktman) is ranked higher than
76% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. TRGT: -8.48 )
TRGT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -54.9   Max: -7.5
Current: -8.48

-54.9
-7.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HGF.Germany
Targacept, Inc., is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a new class of drugs for the treatment of diseases and disorders of the central nervous system. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs, which are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The company's most advanced product candidates are TC-5214, AZD3480 (TC-1734), TC-5619 and AZD1446. It has multiple clinical-stage product candidates and preclinical programs in areas where there are significant medical need and commercial potential, as well as proprietary drug discovery technologies. It also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. In July 2007, it entered into a product development and commercialization agreement with SmithKline Beecham Corporation, doing business as GlaxoSmithKline, and Glaxo Group Limited. The agreement sets forth the terms of an alliance designed to discover, develop and market product candidates that selectively target specified NNR subtypes in five therapeutic focus areas- pain, smoking cessation, addiction, obesity and Parkinson's disease. The company is conducting an ongoing Phase 2b clinical trial of TC-5214 as an augmentation treatment in subjects with major depressive disorder. The company might also conduct development of TC-5214 in one or more other indications. The company and AstraZeneca are conducting an ongoing exploratory Phase 2 trial of AZD3480 in adults with ADHD. TC-5619 is a novel small molecule that the company plans to develop for cognitive dysfunction in schizophrenia or potentially one or more other conditions characterized by cognitive impairment. TC-5619 modulates the activity of the a7 NNR. AZD1446 (TC-6683) is a novel small molecule that it discovered and advanced as part of the preclinical research collaboration that it is conducting with AstraZeneca. AZD1446 modulates the activity of the a4ß2 NNR and is in development for Alzheimer's disease, ADHD or one or more other conditions characterized by cognitive impairment.
» More Articles for TRGT

Headlines

Articles On GuruFocus.com
Weekly Three-Year Low Highlights: ESIO, VJET, TRGT, ZX May 13 2014 
Why Should You Invest Only in High-Quality Companies? Jun 13 2012 
Seth Klarman Buys 25.5 Million Shares of Global Media Conglomerate Vivendi Apr 17 2012 
Seth Klarman Gives Up Targacept; Sold Out Apr 10 2012 
4 Mar 20 2012 
6 Feb 11 2012 
Seth Klarman Latest Portfolio: Buys IDIX, NG, ANV, Sells PDLI, ALR, BBEP Feb 10 2012 
Seth Klarman Feb 08 2012 
comment on TRGT Dec 28 2011 
comment on TRGT Dec 28 2011 


More From Other Websites
Why trader is buying Targacept puts Jul 15 2014
TARGACEPT INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 14 2014
Targacept ends Alzheimer's drug trial after mid-stage failure Jul 14 2014
Targacept ends Alzheimer's drug trial after mid-stage failure Jul 14 2014
News Targacept's Key Drug Failed Phase 2b Trial Shaves 16% From Shares Jul 14 2014
[$$] Targacept Drops Development of Alzheimer's Drug Jul 14 2014
Targacept stops Alzheimer's drug trial after it fails mid-stage Jul 14 2014
Targacept confirms Alzheimer’s trial does not show superiority of TC-1734 Jul 14 2014
Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority of TC-1734 Over... Jul 14 2014
July 14, 2014 Targacept Phase 2b Clinical Trial in Alzheimer’s Disease Does Not Show Superiority... Jul 14 2014
Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis Jun 25 2014
Former NSA Chief Mike McConnell Says Culture, Not Tech, Is Key to Cyber Defense Jun 20 2014
TARGACEPT INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 09 2014
TARGACEPT INC Financials May 16 2014
Weekly Three-Year Low Highlights: ESIO, VJET, TRGT, ZX May 13 2014
TARGACEPT INC Files SEC form 10-Q, Quarterly Report May 08 2014
Targacept 's (TRGT) CEO Stephen Hill on Q1 2014 Results - Earnings Call Transcript May 07 2014
Targacept, Inc. Earnings Call scheduled for 8:30 am ET today May 07 2014
TARGACEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 07 2014
Targacept Reports First Quarter 2014 Financial Results May 07 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide